The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Metronomic cyclophosphamide and bevacizumab for the treatment of recurrent gynecologic carcinosarcoma: A multi-institution, retrospective study.
 
Sara Bouberhan
No Relationships to Disclose
 
Jill S. Hyde
No Relationships to Disclose
 
McKenzie Foxall
No Relationships to Disclose
 
Richard T. Penson
Honoraria - Abbvie; AstraZeneca; Clovis Oncology; Eisai; Genentech/Roche; Janssen Oncology; Mersana; Newlink Genetics; Sutro Biopharma; Tesaro; Vascular Biogenics
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Baxalta; Care4ward; Clovis Oncology; Eisai; Genentech; Janssen Oncology; Merck; Mersana; Sutro Biopharma; Tesaro; Vascular Biogenics
Research Funding - Array BioPharma (Inst); AstraZeneca (Inst); Cerulean Pharma (Inst); Eisai (Inst); Genentech (Inst); Regeneron (Inst); Sanofi (Inst); Tesaro (Inst); Vascular Biogenics (Inst)
Patents, Royalties, Other Intellectual Property - Blackwell Publishing; BMJ; UpToDate
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; Genentech; Tesaro; Vascular Biogenics
Other Relationship - Abbvie; AstraZeneca
 
Rebecca Christian Arend
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; Clovis Oncology; GlaxoSmithKline; KIYATEC; Leap Therapeutics; Merck; VBL Therapeutics